Home > Newsletters > Washington Drug Letter > EMA Posts Q&A to Help Drugmakers With Biosimilar Submission Process
Washington Drug Letter
April 23, 2012 | Vol. 44 No. 17
EMA Posts Q&A to Help Drugmakers With Biosimilar Submission Process
The European Medicines Agency (EMA) has published question-and-answer guidance on marketing applications for biosimilars, providing advice on a number of pre-submission issues, such as requesting an accelerated assessment, and giving detailed answers about review timing.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.